← Back to Search

Behavioral Intervention

Communication Bridge™ for Primary Progressive Aphasia (CB3 Trial)

Phase 2

Waitlist Available

Led By Emily Roglaski, PhD

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

18+ years of age

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 assessment time points through study completion, an average of 1 year, including change over time

Awards & highlights

CB3 Trial Summary

This trial will investigate the effects of two different treatments for adults with mild-moderate Primary Progressive Aphasia (PPA). The goal is to determine how speech-language therapy can improve communication abilities in individuals

Who is the study for?

This trial is for adults with mild to moderate Primary Progressive Aphasia (PPA), including conditions like Pick's Disease and Frontotemporal Dementia. Participants should be able to engage in speech-language therapy.Check my eligibility

What is being tested?

The study compares two evidence-based speech-language therapies using a randomized controlled design, aiming to understand their impact on communication abilities in individuals with PPA.See study design

What are the potential side effects?

Since the interventions are non-medical therapies focused on improving communication, no traditional side effects like those seen with medications are expected.

CB3 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

CB3 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 assessment time points through study completion, an average of 1 year, including change over time

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 assessment time points through study completion, an average of 1 year, including change over time

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 assessment time points through study completion, an average of 1 year, including change over time for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Communication Participation Person Centered Goals

CB3 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Communication Bridge™Experimental Treatment1 Intervention

Participants receive Communication Bridge™, a multi-component, participation-focused, dyadic intervention in which both the person with PPA and their co-enrolled communication partner are intervention recipients. Communication Bridge™ is modelled on the Living with Aphasia: Framework for Outcome Measurement (A-FROM) and the Care Pathway Model that was developed for persons living with primary progressive aphasia. Consistent with participation-focused intervention models personally salient training stimuli are incorporated into all therapy activities in the Experimental arm.

Group II: Evidence-Based Impairment FocusedActive Control1 Intervention

The Control arm includes a non-dyadic intervention in which the person with PPA is the active intervention recipient and their communication partner is in a supporting role. In the Control arm, participants receive a speech-language intervention designed to address impairment and functional limitations, comprised of activities that address word retrieval and 'automatic' speech production using fixed, non-personalized, stimuli across participants.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Communication Bridge™

2018

N/A

~110

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)NIH

1,669 Previous Clinical Trials

28,004,914 Total Patients Enrolled

University of ChicagoLead Sponsor

1,002 Previous Clinical Trials

817,650 Total Patients Enrolled

Western University, CanadaOTHER

239 Previous Clinical Trials

57,283 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to be a participant in this clinical trial?

"To be eligible for enrollment in this research, participants must manifest primary progressive aphasia and have an age between 18 and 100. The study aims to recruit a total of 200 individuals."

Answered by AI

Has the Communication Bridge™ received official approval from the FDA?

"Based on our assessment at Power, the safety of Communication Bridge™ is rated 2 out of 3. This rating reflects that although there is some data supporting its safety, no evidence has been found yet regarding its efficacy in this Phase 2 trial."

Answered by AI

Is this medical study currently open to new participants?

"The information provided on clinicaltrials.gov indicates that the current trial is not actively seeking participants. It was initially posted on June 1st, 2024 and last updated on December 20th, 2023. However, there are currently 131 other ongoing clinical trials that are actively enrolling participants at this time."

Answered by AI

Is the age criterion for participation in this study limited to individuals below 35 years of age?

"Applicants aged between 18 and 100 years old meet the inclusion criteria for this clinical trial. Additionally, there are a total of 12 trials available specifically for individuals under the age of 18, while there are 127 trials dedicated to those over the age of 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Communication Bridge 3 Study

2024. "Communication Bridge 3 Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06191198.

All > Aphasia > Frontotemporal Dementia